Investor Relations
Wound2.Care
Reshaping the Future of Wound Care Through AI + Access.
Wound2.Care is the first AI-powered wound evaluation and scheduling platform built to connect patients, clinics, and providers across all 52 U.S. states and territories.
Our platform transforms a traditionally slow, fragmented, $20 billion market into an intelligent, connected, and transparent care ecosystem — positioning us as the first mover in one of healthcare’s fastest-growing verticals.
⸻
The Market Opportunity
• The U.S. wound care market exceeds $20 billion in annual spending (2025).
• Driven by aging populations, diabetes, and chronic disease, it’s projected to grow beyond $30 billion by 2030.
• Yet the market remains disconnected, with patients struggling to find timely, transparent, and qualified care.
• Millions of wound cases each year still go untreated or mismanaged — resulting in avoidable ER visits, amputations, and hospitalizations.
Wound2.Care is solving that — with AI triage, national scheduling, and real-time pricing for both patients and providers.
⸻
The Wound2.Care Advantage
1. AI Evaluation Technology
Our proprietary AI wound-evaluation engine instantly classifies wound type, severity, and urgency through secure image and data analysis — providing actionable clinical recommendations and routing the patient to the right provider.
2. Nationwide Coverage
Operating in all 52 U.S. states, Wound2.Care connects users with:
• Licensed wound care physicians, nurses, and home-visit providers
• AI-powered triage and scheduling
• Transparent pricing and insurance matching
3. Wound Care House Calls
We’re pioneering “Wound Care House Calls” — bringing advanced care (debridement, NPWT, grafting, biologics) directly to patients’ homes or hotels, coordinated through our AI system.
4. Provider Network Integration
Clinics and independent providers use our dashboard to:
• Receive AI-prequalified patients
• Automate intake and documentation
• Track outcomes and billing transparently
5. Data Intelligence
As Wound2.Care scales, aggregated, de-identified wound data fuels:
• Predictive healing analytics
• National wound trends
• Outcome-based reimbursement insights
⸻
Investment Opportunity
We are seeking: $10 million USD for 10% equity
(Series A Round)
These funds will accelerate:
• AI model development and clinical validation
• Expansion of the provider and house-call network nationwide
• Integration with insurance, EHR, and travel-health platforms
• Marketing and patient acquisition in key states
• Telehealth and international traveler modules
⸻
Meet the Founder – Eli Ofel
Eli Ofel is a serial entrepreneur and the driving force behind Leaa Health. In addition to Leaa, he has launched tech platforms such as Lender.Market, Citizen One, and 02.Market—all built to make essential services smarter, faster, and more personalized.
At Leaa, Eli is leading the design of an AI-powered booking and care system that transforms healthcare into an experience as seamless as ordering a ride.
“We’re building the next great category in healthcare—where technology meets trust, and patients finally come first.”
– Eli Ofel
| Category | Allocation | Description |
|---|---|---|
| AI Development & Data Infrastructure | 25% | Enhancing our proprietary AI wound-evaluation engine, secure data architecture, and predictive analytics capabilities. |
| Provider & Partner Expansion | 25% | Building and onboarding partner clinics, hospitals, and home-visit providers across all 52 U.S. states and territories. |
| Marketing & User Acquisition | 20% | Driving nationwide awareness through patient outreach, provider marketing, SEO, and targeted digital campaigns. |
| Compliance & Regulatory | 10% | Ensuring HIPAA, FDA, and telehealth compliance; securing clinical validation and regulatory filings for AI use in healthcare. |
| Operations & Staff Growth | 10% | Scaling operational capacity with new hires in data science, clinical coordination, and technical support functions. |
| Reserve / Working Capital | 10% | Maintaining strategic liquidity for future R&D, partnerships, and rapid market expansion opportunities. |
| Key Factor | Impact / Advantage |
|---|---|
| First-to-Market AI Evaluation Technology | Wound2.Care is the first and only platform to combine AI-driven wound classification, transparent pricing, and real-time provider scheduling across all 52 states. |
| $20B Market Expanding to $30B by 2030 | The U.S. wound care industry is rapidly growing due to aging populations and chronic disease — positioning Wound2.Care to capture a major share of a $30B market. |
| Scalable Nationwide Platform | Operating in all 52 U.S. states and territories, with a growing network of providers, clinics, and home-visit professionals connected through one AI infrastructure. |
| Recurring Revenue Model | Monetization through AI evaluations, per-visit fees, provider subscriptions, and enterprise data partnerships ensures predictable, scalable recurring revenue. |
| Data Intelligence & Predictive Analytics | Each AI wound evaluation adds to a proprietary national wound database — enabling predictive analytics, research partnerships, and future insurance integrations. |
| Wound Care House Calls Innovation | Revolutionizing access to care through same-day home and hotel visits — powered by AI triage and coordination tools that improve outcomes and reduce hospitalizations. |
| Insurance and Telehealth Integration | Seamlessly integrates with private insurance, Medicare, Medicaid, and telehealth APIs for billing, scheduling, and patient management automation. |
| Proprietary Technology & First-Mover Advantage | Our AI wound evaluation model and cross-state compliance engine create high entry barriers and significant long-term competitive defensibility. |
| Strong Exit Potential | High acquisition potential by major healthcare networks, insurance carriers, or telehealth leaders seeking to expand into AI-driven wound management. |
| Year | Active States | AI Evaluations | Projected Revenue (USD) |
|---|---|---|---|
| 2025 | 30 | 250,000 | $12 Million |
| 2026 | 52 | 1,000,000 | $40 Million |
| 2027 | 52 + (International Expansion) | 3,000,000 + | $100 Million + |
| Year | Projected Valuation (USD) | Investor Equity Value (10%) | Estimated ROI vs. Initial $10M |
|---|---|---|---|
| 2025 | $100 Million | $10 Million | Break-even / Early-stage product scaling |
| 2026 | $250 Million | $25 Million | 2.5 × Return – Post-Series A expansion |
| 2027 | $500 Million | $50 Million | 5 × Return – National dominance / data licensing revenue |
| 2028 | $800 Million | $80 Million | 8 × Return – International rollout + AI SaaS integrations |
| 2029 | $1 Billion + | $100 Million + | 10 × Return – Acquisition or IPO potential |
| 2030 | $1.5 Billion + | $150 Million + | 15 × Return – Projected exit valuation |
Wound2.Care is strategically positioned for multiple high-value exit scenarios within the next 5–7 years. Our proprietary AI evaluation engine, national provider network, and transparent-pricing model make the company an attractive acquisition or IPO candidate as the wound-care market expands from $20 billion (2025) to over $30 billion by 2030.
| Exit Option | Description | Estimated Timeline |
|---|---|---|
| Strategic Acquisition | Potential acquisition by a large telehealth, hospital network, or insurance carrier seeking to expand into AI-driven wound management and home-health infrastructure (e.g., Teladoc, UnitedHealth, Optum, or CVS Health). | 2028 – 2030 |
| Initial Public Offering (IPO) | Pursuing a public listing once nationwide adoption and data-intelligence revenue reach scale. The wound-care sector’s predictable reimbursement model supports long-term investor confidence. | 2029 – 2031 |
| Acquisition by AI / Health-Tech Giant | Sale to a global health-tech or AI company expanding clinical AI portfolios (e.g., Google Health, Amazon Care, or Microsoft Cloud for Healthcare). Wound2.Care’s proprietary dataset and algorithms are a unique asset in digital health. | 2027 – 2030 |
| Private Equity Recapitalization | Secondary sale to healthcare-focused private equity funds after 5×–8× revenue growth, enabling early investors to realize substantial ROI while funding further international expansion. | 2028 – 2029 |
| Long-Term Dividend / Data Licensing Model | Continuous revenue generation through nationwide data licensing, AI SaaS subscriptions, and predictive-analytics tools for hospitals and insurers — providing recurring returns to shareholders. | Ongoing (Post-2027) |
Regardless of the chosen exit path, our goal is to deliver strong investor returns while advancing the standard of wound-care delivery through technology, access, and transparency. A $10 million investment for 10 % equity in Wound2.Care represents participation in the first and only AI-driven wound-care platform with national scale and multi-channel revenue potential.
Patient Reviews for Wound2.Care
Real Stories from Our Patients Across the U.S.
At Wound2.Care, we’re proud to serve patients from New York to Miami, Los Angeles to Chicago, and everywhere in between.
Our mission is simple: deliver expert at-home and in-hotel wound care that’s compassionate, fast, and transparent.
Here’s what real patients have shared about their experiences with our licensed clinicians and AI-powered care system.
⸻
Michael R. – Brooklyn, NY (★★★★★)
“Wound2.Care came to my apartment the same day I submitted my AI wound evaluation. The nurse was incredibly kind and explained each step clearly. My diabetic ulcer improved faster than it ever did before — no waiting rooms, no stress. I highly recommend them to anyone in NYC.”
⸻
Patricia S. – Miami, FL (★★★★★)
“I was staying at a hotel for a business trip when my surgical wound reopened. Within a few hours, Wound2.Care sent a clinician to my hotel room. They cleaned, dressed, and stabilized my wound with full professionalism. It felt like hospital-quality care, but in the comfort of my room.”
⸻
James L. – Hoboken, NJ (★★★★☆)
“I used their AI photo assessment late on a Sunday and got a same-day appointment the next morning. The entire process was seamless — transparent pricing, no hidden fees, and great communication. It’s the easiest medical experience I’ve ever had.”
⸻
Angela K. – Los Angeles, CA (★★★★★)
“After cosmetic surgery, I needed daily wound management. Wound2.Care’s clinicians handled everything at my home — from sterile dressing changes to NPWT setup. Their AI app tracked my healing, which kept my surgeon updated remotely. This service is a game changer.”
⸻
David P. – Chicago, IL (★★★★★)
“I travel for work constantly, so finding reliable wound care was always a hassle. Wound2.Care met me at my hotel, brought all supplies, and handled my care discreetly. I wish this service existed years ago.”
⸻
Sarah G. – Long Island, NY (★★★★★)
“My father has diabetic foot ulcers, and Wound2.Care’s team has been visiting our home weekly. Their clinicians are punctual, respectful, and extremely thorough. The AI reports let us monitor his progress online, which gives us peace of mind.”
⸻
Alex M. – Orlando, FL (★★★★★)
“I had a small burn that became infected while on vacation. I booked through Wound2.Care’s AI evaluation and had a same-day hotel visit. They treated it quickly and followed up virtually a few days later — amazing service for travelers.”
⸻
Maria D. – Newark, NJ (★★★★★)
“Professional and trustworthy. The clinician explained my pressure ulcer treatment plan, changed my dressing, and gave me practical tips to prevent recurrence. I’ve recommended them to everyone I know.”
⸻
⭐ Average Patient Rating: 4.9 / 5
Our clients
SoftBank, Disney, ViacomCBS (now Paramount Global) ,Uber, Sharing, Nike, Atlantic Records, American Eagle Outfitters, Warner Bros, New York Rangers (NHL), Jacob & Co, ZARA, Eileen Fisher, Target and more.
Service Areas
Leaa Health provides home doctor visits in:
New York City
Upper East Side, Tribeca, SoHo, Battery Park City, Chelsea, Lincoln Square, and more
Brooklyn
DUMBO, Cobble Hill, Brooklyn Heights, Williamsburg
New Jersey
Short Hills, Montclair, Hoboken, Saddle River, Tenafly, Jersey City
Miami, FL
Aventura, Coral Gables, Brickell, Coconut Grove, Miami Beach
Texas
Dallas-Fort Worth Area, Houston, Austin, San Antonio, Prosper, Celina
© 2024 Wound2.Care Health Technologies. All Rights Reserved.
Wound2.Care™, the Wound2.Care logo, and the tagline “From Wound to Care” are trademarks of Wound2.Care Health Technologies.
All content, including but not limited to text, AI evaluation logic, images, design, software code, and datasets, is protected under U.S.
and international copyright and intellectual property laws.
No part of this platform may be reproduced, distributed, or transmitted in any form or by any means without prior written
permission from Wound2.Care Health Technologies.